


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-46 (Cancelled)

47. (Currently amended) A crystalline hydrogen succinate salt ~~or a crystalline malonate salt~~ of the compound of formula (I);



(I)

48-49. (Cancelled).

50. (Currently amended) The crystalline hydrogen succinate salt of claim 47[[48]], wherein the salt comprises an alpha crystal form characterized by one or more of:

- a. an X-Ray powder diffractogram obtained using CuK_{α1} radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 9.36; 10.23; 11.81; 13.45; 16.21; 16.57; 17.49; 18.89; 19.20; 19.63; 20.01; 20.30; 21.15; 21.53; 21.93; 22.34; 24.37; 25.34; 27.27; and 29.65;
- b. an X-Ray powder diffractogram as shown in Figure 1; and

- c. a Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 139-141 °C.

51-57. (Cancelled).

58. (Currently amended) A pharmaceutical composition comprising the crystalline hydrogen succinate salt ~~or the crystalline malonate salt~~ of claim 47 and at least one pharmaceutically acceptable carrier, filler or diluent.

59. (Currently amended) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the crystalline hydrogen succinate salt ~~or the crystalline malonate salt~~ of claim 47, wherein the disease or disorder is selected from the group consisting of an anxiety disorder, depression, schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.

60. (Cancelled).

61. (Currently amended) The method of claim 59, wherein the disease or disorder is schizophrenia, ~~Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder or mania in bipolar disorder.~~

62. (Previously presented) The method of claim 61, wherein the schizophrenia comprises positive symptoms, negative symptoms, depressive symptoms, or a combination thereof.

63. (Previously presented) The method of claim 59, wherein the disease or disorder is selected from the group consisting of Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.

64. (Cancelled).

65. (New) The crystalline hydrogen succinate salt of claim 47, wherein the salt comprises a beta crystal form characterized by one or more of:
- a. an X-Ray powder diffractogram obtained using $\text{CuK}_{\alpha 1}$ radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 8.1; 10.5; 11.4; 14.0; 14.6; 15.6; 15.7; 16.2; 17.2; 17.5; 17.9; 18.4; 18.9; 19.2; 20.3; 21.0; 21.9; 22.5; 23.3; and 26.3;
 - b. an X-Ray powder diffractogram as shown in Figure 2; and
 - c. a Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 135-138 °C.
66. (New) The pharmaceutical composition of claim 58, wherein the salt comprises an alpha crystal form characterized by one or more of:
- a. an X-Ray powder diffractogram obtained using $\text{CuK}_{\alpha 1}$ radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 9.36; 10.23; 11.81; 13.45; 16.21; 16.57; 17.49; 18.89; 19.20; 19.63; 20.01; 20.30; 21.15; 21.53; 21.93; 22.34; 24.37; 25.34; 27.27; and 29.65;
 - b. an X-Ray powder diffractogram as shown in Figure 1; and
 - c. a Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 139-141 °C.
67. (New) The pharmaceutical composition of claim 58, wherein the salt comprises a beta crystal form characterized by one or more of:
- a. an X-Ray powder diffractogram obtained using $\text{CuK}_{\alpha 1}$ radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 8.1; 10.5; 11.4; 14.0; 14.6; 15.6; 15.7; 16.2; 17.2; 17.5; 17.9; 18.4; 18.9; 19.2; 20.3; 21.0; 21.9; 22.5; 23.3; and 26.3;
 - b. an X-Ray powder diffractogram as shown in Figure 2; and
 - c. a Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 135-138 °C.

68. (New) The method of claim 59, wherein the salt comprises an alpha crystal form characterized by one or more of:
- a. an X-Ray powder diffractogram obtained using $\text{CuK}_{\alpha 1}$ radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 9.36; 10.23; 11.81; 13.45; 16.21; 16.57; 17.49; 18.89; 19.20; 19.63; 20.01; 20.30; 21.15; 21.53; 21.93; 22.34; 24.37; 25.34; 27.27; and 29.65;
 - b. an X-Ray powder diffractogram as shown in Figure 1; and
 - c. Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 139-141 °C.
69. (New) The method of claim 59, wherein the salt comprises a beta crystal form characterized by one or more of:
- a. an X-Ray powder diffractogram obtained using $\text{CuK}_{\alpha 1}$ radiation ($\lambda=1.5406 \text{ \AA}$) that has main peaks at the following 2θ -angles: 8.1; 10.5; 11.4; 14.0; 14.6; 15.6; 15.7; 16.2; 17.2; 17.5; 17.9; 18.4; 18.9; 19.2; 20.3; 21.0; 21.9; 22.5; 23.3; and 26.3;
 - b. an X-Ray powder diffractogram as shown in Figure 2; and
 - c. a Differential Scanning Calorimetry (DSC) trace that shows an endotherm with an onset temperature from 135-138 °C.